Velmanase alfa - Chiesi Farmaceutici
Alternative Names: ALPHA-MAN project; Lamazym; Lamzede; Recombinant lysosomal alpha-D-mannosidase; Recombinant lysosomal alpha-mannosidase; rhLAMAN; velmanase alfa-tycvLatest Information Update: 01 Mar 2023
At a glance
- Originator Zymenex A/S
- Developer Chiesi Farmaceutici; Zymenex A/S
- Class Mannosidases; Recombinant proteins
- Mechanism of Action Alpha-mannosidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alpha-Mannosidosis
Most Recent Events
- 24 Feb 2023 US FDA label for velmanase alfa has black box warning for hypersensitivity reactions including anaphylaxis for LAMZEDE
- 16 Feb 2023 Registered for Alpha-Mannosidosis (In adolescents, In children, In adults) in USA (IV)
- 16 Feb 2023 Chiesi Farmaceutici announces intention to launch Velmanase alfa for Alpha-Mannosidosis in USA